Healthleap has raised $38 million to expand an artificial-intelligence platform designed to flag hospital patients who may need closer clinical review. TechCrunch reported that the financing combines an $8 million seed round co-led by Sequoia Capital and First Round Capital with a $30 million Series A led by Hummingbird Ventures. The private company did not disclose its valuation.
The platform connects to hospital electronic health records and analyzes both structured information, such as laboratory results and vital signs, and unstructured clinicians’ notes. It then places a risk score inside the care team’s existing workflow. Healthleap says the software does not diagnose patients; it identifies signals that warrant human review.
The company began with malnutrition screening and now says it operates in more than 50 hospitals, up from three hospital partners a year earlier. Management also cited programs for delirium, aspiration pneumonia, pressure ulcers and congestive-heart-failure readmission risk, although several newer uses remain under clinical validation. Healthleap reported more than tenfold revenue growth over the past year without disclosing revenue, contract value or valuation.
For investors, the funding illustrates continuing demand for AI tools that can demonstrate a measurable operational benefit inside existing health-care systems. Healthleap uses multiyear contracts priced partly by licensed bed count and also offers outcome-based pricing. Those claims still depend heavily on company-reported results rather than audited public financials. The new capital is intended for engineering, product, sales and customer success as the company works toward more than 40 conditions and eventual expansion beyond inpatient care.